In living systems, proteins usually team up into “molecular machinery” implementing several protein-to-protein physical contacts – or protein-protein interactions (PPIs) – to exert biological effects at both cellular and systems levels. Deregulations of protein-protein contacts have been associated with a huge number of diseases in a wide range of medical areas, such as oncology, cancer immunotherapy, infectious diseases, neurological disorders, heart failure, inflammation and oxidative stress. PPIs are very complex and usually characterised by specific shape, size and complementarity. The protein interfaces are generally large, broad and shallow, and frequently protein-protein contacts are established between non-continuous epitopes, that conversely are dislocated across the protein interfaces. For this reason, in the past two decades, PPIs were thought to be “undruggable” targets by the scientific research community with scarce or no chance of success. However, in recent years the Medicinal Chemistry frontiers have been changing and PPIs have gained popularity amongst the research groups due to their key roles in such a huge number of diseases. Until recently, PPIs were determined by experimental evidence through techniques specifically developed to target a small group of interactions. However, these methods present several limitations in terms of high costs and labour- and time-wasting. Nowadays, a large number of computational methods have been successfully applied to evaluate, validate, and deeply analyse the experimentally determined protein interactomes. In this context, a high number of computational tools and techniques have been developed, such as methods designed to construct interaction databases, quantum mechanics and molecular mechanics (QM/MM) to study the electronic properties, simulate chemical reactions, and calculate spectra, and all-atom molecular dynamics simulations to simulate temporal and spatial scales of inter- and intramolecular interactions. These techniques have allowed to explore PPI networks and predict the related functional features. In this PhD work, an extensive use of computational techniques has been reported as valuable tool to explore protein-protein interfaces, identify their hot spot residues, select small molecules and design peptides with the aim of inhibiting six different studied PPIs. Indeed, in this thesis, a success story of in silico approaches to PPI study has been described, where MD simulations, docking and pharmacophore screenings led to the identification of a set of PPI modulators. Among these, two molecules, RIM430 and RIM442, registered good inhibitory activity with IC50 values even within the nanomolar range against the interaction between MUC1 and CIN85 proteins in cancer disease. Furthermore, computational alanine scanning, all-atom molecular dynamics simulations, docking and pharmacophore screening were exploited to (1) rationally predict three potential interaction models of NLRP3PYD-ASCPYD complex involved in inflammatory and autoimmune diseases; (2) identify a potentially druggable region on the surface of SARS-CoV-2 Spike protein interface and select putative inhibitors of the interaction between Spike protein and the host ACE2 receptor against COVID-19 (CoronaVIrus Disease 2019); (3) investigate intramolecular modifications as a consequence of a point mutation on C3b protein (R102G) associated with the age-related macular degeneration (AMD) disease; (4) design non-standard peptides to inhibit transcriptional events associated with HOX-PBX complex involved in cancer diseases; and (5) to optimise a patented peptide sequence by designing helix-shaped peptides embedded with the hydrogen bond surrogate approach to tackle cocaine abuse relapses associated with Ras-RasGRF1 interaction. Although all the herein exploited techniques are based on predictive calculations and need experimental evidence to confirm the findings, the results and molecular insights retrieved and collected show the potential of the computer-aided drug design applied to the Medicinal Chemistry, guaranteeing labour- and time-saving to the research groups. On the other hand, computing ability, improved algorithms and fast-growing data sets are rapidly fostering advances in multiscale molecular modelling, providing a powerful emerging paradigm for drug discovery. It means that more and more research efforts will be done to invest in novel and more precise computational techniques and fine-tune the currently employed methodologies.